319 related articles for article (PubMed ID: 35716043)
1. Proteogenomic characterization of cholangiocarcinoma.
Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
[TBL] [Abstract][Full Text] [Related]
2. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
[TBL] [Abstract][Full Text] [Related]
3. Role of molecular genetics in the clinical management of cholangiocarcinoma.
Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
[TBL] [Abstract][Full Text] [Related]
4. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies.
Hong JH; Yong CH; Heng HL; Chan JY; Lau MC; Chen J; Lee JY; Lim AH; Li Z; Guan P; Chu PL; Boot A; Ng SR; Yao X; Wee FYT; Lim JCT; Liu W; Wang P; Xiao R; Zeng X; Sun Y; Koh J; Kwek XY; Ng CCY; Klanrit P; Zhang Y; Lai J; Tai DWM; Pairojkul C; Dima S; Popescu I; Hsieh SY; Yu MC; Yeong J; Kongpetch S; Jusakul A; Loilome W; Tan P; Tan J; Teh BT
Gut; 2024 May; 73(6):966-984. PubMed ID: 38050079
[TBL] [Abstract][Full Text] [Related]
5. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
[TBL] [Abstract][Full Text] [Related]
6. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
7. Refining Classification of Cholangiocarcinoma Subtypes via Proteogenomic Integration Reveals New Therapeutic Prospects.
Cho SY; Hwang H; Kim YH; Yoo BC; Han N; Kong SY; Baek MJ; Kim KH; Lee MR; Park JG; Han SS; Lee WJ; Park C; Park JB; Kim JY; Park SJ; Woo SM
Gastroenterology; 2023 Jun; 164(7):1293-1309. PubMed ID: 36898552
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Borad MJ; Gores GJ; Roberts LR
Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
[TBL] [Abstract][Full Text] [Related]
9.
Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
[TBL] [Abstract][Full Text] [Related]
10. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
[TBL] [Abstract][Full Text] [Related]
11. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
12. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities.
Lin J; Dai Y; Sang C; Song G; Xiang B; Zhang M; Dong L; Xia X; Ma J; Shen X; Ji S; Zhang S; Wang M; Fang H; Zhang X; Wang X; Zhang B; Zhou J; Fan J; Zhou H; Gao D; Gao Q
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863823
[TBL] [Abstract][Full Text] [Related]
13. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.
Goeppert B; Stichel D; Toth R; Fritzsche S; Loeffler MA; Schlitter AM; Neumann O; Assenov Y; Vogel MN; Mehrabi A; Hoffmann K; Köhler B; Springfeld C; Weichenhan D; Plass C; Esposito I; Schirmacher P; von Deimling A; Roessler S
Gut; 2022 Feb; 71(2):391-401. PubMed ID: 33468537
[TBL] [Abstract][Full Text] [Related]
15. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
[TBL] [Abstract][Full Text] [Related]
16. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
17. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
18. Proteomic and Phosphoproteomic Profiling Reveals the Oncogenic Role of Protein Kinase D Family Kinases in Cholangiocarcinoma.
Lu Y; Li X; Zhao K; Shi Y; Deng Z; Yao W; Wang J
Cells; 2022 Sep; 11(19):. PubMed ID: 36231050
[TBL] [Abstract][Full Text] [Related]
19. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine.
Gopal P; Robert ME; Zhang X
Arch Pathol Lab Med; 2024 Mar; 148(3):359-370. PubMed ID: 37327187
[TBL] [Abstract][Full Text] [Related]
20. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
